Man lives for 100 days with artificial titanium heart in new trial
An Australian man lived for 100 days with an artificial titanium heart while he awaited a donor transplant, the longest period to date of someone with the technology.
The patient, a man in his 40s who declined to be identified, received the implant during surgery at St. Vincent's Hospital Sydney last November.
In February, he became the first person worldwide to leave hospital with the device, which kept him alive until a heart donor became available earlier this month.
According to a statement issued Wednesday by St Vincent's Hospital, Monash University and BiVACOR, the US-Australian company behind the device, the man, who had severe heart failure, was 'recovering well.'
The ability of the device to sustain him for so long is being celebrated as a sign the artificial heart could potentially offer a long-term option for people suffering heart failure. The device is still being trialed and has not yet been approved for general use.
BiVACOR's founder, Australian bioengineer Daniel Timms, who invented the device following his father's death from heart disease, said it was 'exhilarating to see decades of work come to fruition.'
'The entire BiVACOR team is deeply grateful to the patient and his family for placing their trust in our Total Artificial Heart,' he said in the statement. 'Their bravery will pave the way for countless more patients to receive this lifesaving technology.'
The BiVACOR Total Artificial Heart (TAH) has a single moving part, a levitated rotor that's held in place by magnets. As the name suggests, it's constructed from titanium and there are no valves or mechanical bearings that may be susceptible to wear.
It pumps blood to the body and the lungs, replacing both ventricles of a failing heart.
Cardiovascular diseases are the leading cause of death globally killing around 18 million people each year, according to the World Health Organization.
The long-term ambition is to use the device to save more people who languish on waiting lists for suitable donors. According to the US Health Department, about 3,500 people received heart transplants in 2024. Around 4,400 joined the waiting list the same year.
Professor Chris Hayward, from the Victor Chang Cardiac Research Institute, said the BiVACOR heart ushered in 'a whole new ball game for heart transplants.'
'Within the next decade we will see the artificial heart becoming the alternative for patients who are unable to wait for a donor heart or when a donor heart is simply not available,' said Hayward, who is overseeing the Australian patient's recovery and was involved in preparing the device for clinical trials.
The device has already been tested in the Food and Drug Administration's Early Feasibility Study in the United States, which saw five patients successfully implanted with the device.
The first was last July, when a 58-year-old man suffering end-stage heart failure received the implant during surgery at Texas Medical Center. It kept him alive for eight days until a donor was available.
Four other patients followed in the study, which examined the safety and performance of the device, while they waited for a donor transplant. It's hoped the trial will expand to 15 patients.
The Australian implant was the first in a series planned by Monash University's Artificial Heart Frontiers Program, a 50 million Australian dollar ($31 million) program to develop and commercialize three devices to treat heart failure.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
28 minutes ago
- New York Post
Chinese researchers' alleged plot to smuggle crop-killing fungus into US is an ‘attack on US food supply': feds
National security authorities and members of Congress are raising alarm over the alleged plot by two romantically involved Chinese researchers to smuggle samples of a dangerous crop-killing fungus into the US. Yunquing Jian, 33, a Communist Party loyalist and lab researcher at the University of Michigan who received Chinese government funding for her work, plotted the illicit transport of the pathogen with her boyfriend, Zunyong Liu, 34, the FBI alleged. Liu was was caught at Detroit Metropolitan Airport last July after allegedly attempting to sneak packages of Fusarium graminearum into the country, the feds said. 'This is an attack on the American food supply,' one senior Trump administration official told The Post. Advertisement 4 Yunqing Jian (pictured) initially denied that she was aware of her boyfriend's intent to smuggle the pathogen. University of Michigan The fungus is already present in the US, but if it was manipulated to become resistant to treatment or to spread more easily, it could have the potential to devastate American farms, one expert told The Post. The US should be testing the fungus sample for any evidence it's been tampered with, the expert added. There are similar allegations that the virus that causes COVID-19 was enhanced by China's Wuhan Institute of Virology as part of US-funded 'gain-of-function' research of the naturally occurring SARS pathogen. China denies that COVID leaked from the lab, but US intel agencies now say that appears to be the most likely cause of the pandemic. Advertisement 'The CCP will use every tool in its warfare toolbox to cripple the United States and bring us to our knees. A pathogen like this, if successfully introduced into a crop, could inflict significant economic loss for U.S. agriculture producers,' House Intelligence Committee Chairman Rick Crawford (R-Ark.) told The Post. Sen. Joni Ernst (R-Iowa) said it appears the FBI may have intercepted a 'potential bioweapon.' 'We are very fortunate the Trump administration and federal law enforcement stopped this potential bioweapon before it compromised our nation's food supply,' Ernst told The Post. 4 Chinese national Yunqing Jian, 33, a University of Michigan lab researcher, is charged with her fellow researcher boyfriend, Zunyong Liu, of conspiring to smuggle a potentially dangerous fungal pathogen into the US. Sanilac County Jail Advertisement 'This is exactly why I have always said and will continue to say – food security is national security. Between this latest bioweapon and China's highly-concerning purchases of U.S. farmland around our military bases, we must stay on guard against the threat from Communist China in our own backyard.' According to the feds, the Chinese couple discussed how they could smuggle Fusarium graminearum into the US — a biological pathogen considered 'a potential agroterrorism weapon' capable of destroying crops and poisoning both livestock and humans, according to a criminal complaint filed in federal court in Michigan Monday. Both Jian and Liu were charged Monday in a federal criminal complaint with conspiracy, smuggling goods into the US, false statements and visa fraud. 'The bacteria infects wheat, barley, corn and rice. When it does, it can devastate crops,' one national security source who specializes in agricultural microbiology told The Post. Advertisement 'The key question is if the bacterial strain being brought in has been modified to make it resistant to treatment or to make it more pathogenic.' 4 Liu was caught at Detroit Metropolitan Airport last July with four plastic baggies containing 'fibrous material' infected with the pathogen. AP The source added that it could be dangerous 'if the Chinese manipulated the strain' and that federal investigators should 'have a genome sequence done' on the samples Jian and Liu allegedly conspired to smuggle into the country. On July 27, 2024, Liu, who works as a researcher at Zhejiang University in Hangzhou, arrived in Detroit on a Delta flight from Shanghai and was interviewed by Customs and Border Patrol agents about the purpose of his travel. He claimed he was in the US to visit Jian, a lab researcher at the University of Michigan whom he identified as his girlfriend. Upon searching his belongings, agents found four plastic baggies containing 'fibrous material' infected with the pathogen, as well as a round piece of filter paper with a series of circles drawn on it, concealed in his backpack in a ball of wadded up tissues. According to the criminal complaint, Liu initially denied the items were his, suggesting someone else had put them into his bag without his knowledge. However he later admitted they were different strains of Fusarium graminearum he intended to research at the Molecular Plant-Microbe Interaction (MPMI) Laboratory at the University of Michigan, where Jian conducts research on similar pathogens. He also acknowledged he hid the materials when traveling to the US because he knew border patrol agents would confiscate them if they were discovered. Advertisement The circled filter paper found in his possession contained 10 separate coded samples, including one that 'would allow a researcher to propagate live Fusarium graminearum,' the complaint states. Liu told investigators that he planned to clone the different strains and make more samples if the experiments on the bagged materials failed. He was denied entry into the US and fast-tracked for removal to China. While searching one of Liu's cell phones, they found an article in PDF form titled '2018 Plant-Pathogen Warfare under Changing Climate Conditions.' Authorities said the article specifically referenced Fusarium graminearum as 'an example of a destructive disease and pathogen for crops' and is 'responsible for billions of dollars in economic losses worldwide each year.' 4 Fusarium graminearum can have a devastating effect on staple US crops including wheat, barley, corn and rice. AP Advertisement The FBI interviewed Jian at the MPMI Laboratory in February, where she first claimed she only learned of the alleged smuggling scheme when Liu was caught by CBP, and denied assisting him in his research of Fusarium graminearum. Upon searching Jian's cell phone, the FBI said it discovered a document she signed originating from Zhejiang University, where Liu conducts research on the pathogen, which included a loyalty pledge to 'adhere to the four basic principles' and 'support the leadership of the Communist Party of China.' FBI Special Agent Edward Nieh said in his affidavit that one of the principles Jian signed her allegiance to includes 'upholding Mao Zedong thought and Marxism-Leninism.' Investigators said she signed the document Jan. 11, 2024, just six months before Liu allegedly flew to Detroit with the samples in tow. Advertisement Further investigation into Liu and Jian's communications indicate it wasn't the first time the pair had discussed smuggling the fetid fungus into the US. One unearthed exchange from Aug. 12, 2022 on the Chinese messaging app WeChat reveals the couple scheming on how to sneak the seeds past US customs officials, with Liu advising Jian to hid the materials in her shoes. A day later, Jian arrived at San Francisco International Airport on a United Airlines flight from Seoul. Authorities reviewed records from her entry and found she did not declare she was importing any biological materials. Rutgers University molecular biologist Dr. Richard Ebright told The Post that Fusarium graminearum causes estimated losses of $200-400 million to US agriculture every year. Advertisement However, he said, the fungus has been endemic in the US for more than 40 years, and that new introduction of the organism into the US does not, by itself, pose a new threat. 'Importation of Fusarium graminearum without a USDA PPQ526 permit should not have occurred,' he said. 'However, unless the imported strain was a new strain having enhanced transmissibility or virulence, its importation likely posed no threat to US agriculture or US security,' he added, noting that if Jian had gone through proper permitting procedure to obtain the pathogen, it 'almost certainly would have been approved and arrests would not have occurred.' Jian, who received a J1 visa to conduct research as a postdoctoral scholar at a University of Texas lab, was a postdoctoral fellow at the University of Michigan before being offered a job in August 2023. The University of Michigan did not respond to The Post's questions about whether she is still employed there following the allegations. The Post also reached out to Jian at her university email address but did not hear back. Liu secured a B2 tourist visa in March 2024, which does not allow foreign nationals to perform work or scientific research during their visit. Jian was temporarily detained by authorities on June 3 until her detention hearing scheduled for Thursday at 1 p.m. Her case has been assigned to the public defender's office but an attorney had not been named by Wednesday evening. Liu remains at large with a warrant out for his arrest.
Yahoo
2 hours ago
- Yahoo
Europe suffers its largest diphtheria outbreak in 70 years
The largest diphtheria outbreak to strike Western Europe in 70 years has been affecting vulnerable people such as migrants and the homeless since 2022, new research said Wednesday. Diphtheria is a highly contagious bacterial infection that can attack the respiratory tract and spread throughout the body, causing a sore throat, fever and other symptoms. For unvaccinated people, it can be fatal in around 30 percent of cases, and is deadlier for children, according to the World Health Organization. In 2022, there was an unusual surge in the bacteria that causes diphtheria -- Corynebacterium diphtheriae -- in several European countries, particularly among recently arrived migrants, according to a study in the New England Journal of Medicine. That year 362 cases were recorded by the European Centre for Disease Prevention and Control. Contact tracing and screening helped tamp down the outbreak, but rare infections have continued to be recorded, the researchers said. A total of 536 cases, including three deaths, have been recorded across Europe since the start of 2022. Patient samples from 10 countries showed that 98 percent of the cases were in males with an average age of 18. Almost all had recently migrated. "The outbreak, which mainly affected migrants from Afghanistan and Syria, was not the result of people being infected in their countries of origin, but during their migration journeys or in their places of accommodation in European countries," said a joint statement from France's public health agency and the Pasteur Institute. The genetic similarities between the strains seen in people from different countries suggests that there was a "recent point of contact, outside the country of origin" at the source of the outbreak, the statement added. The exact areas affected by the outbreak remains unclear. But a genetic link between the 2022 strain and the one detected in Germany this year indicates that "the bacteria continues to circulate quietly in Western Europe," the statement said. Vaccination is very effective at fending off diphtheria, and the researchers emphasised the importance of immunisation programmes for the general public. They also called for European nations to do more to ensure their most vulnerable people avoid contracting the disease. That included raising awareness of the symptoms among doctors and those in contact with migrants and the homeless, as well as increasing access to vaccines and antibiotic drugs. ic-dl/giv
Yahoo
3 hours ago
- Yahoo
Boston Scientific (NYSE:BSX) Secures US$30-45 Million Deal with Bittium for ECG Devices
Boston Scientific recently entered into a significant agreement with Bittium Biosignals Ltd. to supply ECG devices, valued between USD 30 to 45 million, which strengthens their cardiac diagnostics offerings. Despite this positive development, Boston Scientific's share price saw a modest decline of 1.54% over the last quarter. This movement is in line with broader market conditions, which have remained flat in recent days and risen over the past year. Positive earnings results and future growth projections would have added weight to broader market moves, maintaining the company's alignment with general market trends. Be aware that Boston Scientific is showing 1 warning sign in our investment analysis. AI is about to change healthcare. These 22 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. The recent agreement between Boston Scientific and Bittium Biosignals Ltd. holds significant potential for bolstering the company's cardiac diagnostics segment. The deal, valued at US$30 to 45 million, could lead to improved revenue and earnings forecasts, given the expected expansion in product offerings. This development might offset some negative factors, such as tariffs and regulatory pressures impacting earnings, by providing a pathway for revenue growth in key markets. Over the past five years, Boston Scientific's shares have delivered a total return, including dividends, of 169.47%. This performance illustrates the company's longer-term growth despite short-term volatility, such as the recent 1.54% share price decline over the last quarter. In comparison, over the past year, Boston Scientific has exceeded both the US Market and US Medical Equipment industry performances, returning more than 12.6% and 9% respectively. The positive uptick in cardiac diagnostics may influence future revenue and earnings forecasts, potentially improving the company's profit margin, which analysts expect to grow from 11.6% to 16.9% over three years. Meanwhile, the share price's current discount to the consensus analyst price target suggests room for growth, as the target is US$117.02, approximately 10.3% above the present share price of US$104.12. Investors should weigh these aspects against market dynamics and the company's ability to capitalize on its new innovations and acquisitions. Click to explore a detailed breakdown of our findings in Boston Scientific's financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:BSX. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
